(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 148.14% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Verastem's revenue in 2025 is $13,379,000.On average, 11 Wall Street analysts forecast VSTM's revenue for 2025 to be $1,259,395,473, with the lowest VSTM revenue forecast at $785,285,831, and the highest VSTM revenue forecast at $1,935,435,758. On average, 11 Wall Street analysts forecast VSTM's revenue for 2026 to be $6,510,994,465, with the lowest VSTM revenue forecast at $3,173,863,565, and the highest VSTM revenue forecast at $10,362,968,371.
In 2027, VSTM is forecast to generate $14,064,362,384 in revenue, with the lowest revenue forecast at $9,188,378,426 and the highest revenue forecast at $22,857,426,854.